Prevessin-Moens, France

Nazih Ammoury



Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Nazih Ammoury: Innovator in Multiple Sclerosis Treatment

Introduction

Nazih Ammoury is a notable inventor based in Prevessin-Moens, France. He has made significant contributions to the field of medicine, particularly in the treatment of multiple sclerosis. With a total of 3 patents to his name, Ammoury is recognized for his innovative approaches to healthcare.

Latest Patents

One of his latest patents involves a Cladribine regimen for treating multiple sclerosis. This invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy. This advancement holds promise for improving treatment outcomes for patients facing challenges with existing therapies.

Career Highlights

Nazih Ammoury is currently associated with Merck Serono S. A., a leading biopharmaceutical company. His work at Merck Serono has allowed him to focus on developing innovative solutions for complex medical conditions. His dedication to research and development has positioned him as a key figure in the medical community.

Collaborations

Throughout his career, Ammoury has collaborated with esteemed colleagues, including H James Brentzel, Jr. and Maria Lopez-Bresnahan. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of medical research.

Conclusion

Nazih Ammoury is a distinguished inventor whose work in the treatment of multiple sclerosis has the potential to change lives. His innovative patents and collaborations reflect his commitment to advancing medical science. His contributions continue to inspire future research and development in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…